Business Description
Acrivon Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US0048901096
Total Employee Number:
76Description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 40.47 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 35 | |||||
3-Year EPS without NRI Growth Rate | 35.6 | |||||
3-Year FCF Growth Rate | 39.9 | |||||
3-Year Book Growth Rate | -23 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 2.37 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.48 | |||||
9-Day RSI | 70.23 | |||||
14-Day RSI | 66.49 | |||||
3-1 Month Momentum % | -8.07 | |||||
6-1 Month Momentum % | -12.94 | |||||
12-1 Month Momentum % | 12.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.98 | |||||
Quick Ratio | 8.98 | |||||
Cash Ratio | 8.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13 | |||||
Shareholder Yield % | 1.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -60.36 | |||||
ROA % | -53.82 | |||||
ROIC % | -406.86 | |||||
3-Year ROIIC % | 140.65 | |||||
ROC (Joel Greenblatt) % | -1072.01 | |||||
ROCE % | -63.43 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.8 | |||||
Price-to-Tangible-Book | 0.8 | |||||
EV-to-EBIT | 0.13 | |||||
EV-to-EBITDA | 0.13 | |||||
EV-to-Forward-Revenue | 0.14 | |||||
EV-to-FCF | 0.16 | |||||
| Price-to-Net-Current-Asset-Value | 0.89 | |||||
| Price-to-Net-Cash | 0.9 | |||||
Earnings Yield (Greenblatt) % | 769.23 | |||||
FCF Yield % | -78.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACRV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acrivon Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2 | ||
| Beta | 2.1056 | ||
| 3-Year Sharpe Ratio | -0.32 | ||
| 3-Year Sortino Ratio | -0.42 | ||
| Volatility % | 64.7 | ||
| 14-Day RSI | 66.49 | ||
| 14-Day ATR ($) | 0.124151 | ||
| 20-Day SMA ($) | 1.71775 | ||
| 12-1 Month Momentum % | 12.12 | ||
| 52-Week Range ($) | 1.2002 - 3.56 | ||
| Shares Outstanding (Mil) | 42.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acrivon Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acrivon Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 30 days | ||
| General meeting for 2026 | 2026-06-17 13:00 | 1.49 (-1.97%) | ||
| TD Cowen\'s 7(th) Annual Oncology Innovation Summit | 2026-05-26 09:00 | 1.75 (-3.85%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.89 (-1.05%) | ||
| Annual report for 2025 | 2026-03-26 | 1.52 (-5.59%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 1.64 (-1.20%) | ||
| TD Cowen 46(th) Annual Health Care Conference | 2026-03-02 13:50 | 1.51 (-15.64%) | ||
| Virtual Corporate R&D Event | 2026-01-08 08:30 | 2.95 (-10.88%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 2.28 (+8.57%) |
Show
Entries
Acrivon Therapeutics Inc Frequently Asked Questions
What is Acrivon Therapeutics Inc(ACRV)'s stock price today?
The current price of ACRV is $1.99. The 52 week high of ACRV is $3.56 and 52 week low is $1.20.
When is next earnings date of Acrivon Therapeutics Inc(ACRV)?
The next earnings date of Acrivon Therapeutics Inc(ACRV) is 2026-08-13 Est..
Does Acrivon Therapeutics Inc(ACRV) pay dividends? If so, how much?
Acrivon Therapeutics Inc(ACRV) does not pay dividend.
Guru Commentaries on NAS:ACRV
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment | 2026-01-28 |
Articles on Acrivon Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers